Home › Meningioma › California › San Diego
Meningioma clinical trials in San Diego, CA
5 studies for Meningioma are looking for participants at sites in and around San Diego (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
RecruitingPhase 2
- UC San Diego Moores Cancer Center, La Jolla · 11 mi away
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
RecruitingPhase 2
- University of California San Diego - Moores Cancer Center, La Jolla · 11 mi away
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Intracranial Lesions
RecruitingPhase 2
- Moores Cancer Center, San Diego
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
RecruitingObservational study
- UCSD Moores Cancer Center, La Jolla · 11 mi away
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
RecruitingObservational study
- Moores Cancer Center, San Diego
Meningioma trials in other cities
- New York City, NY8 studies
- Miami, FL7 studies
- Boston, MA6 studies
- Columbus, OH6 studies
- Jacksonville, FL5 studies
- San Francisco, CA5 studies
- Atlanta, GA5 studies
- Phoenix, AZ4 studies
- Houston, TX4 studies
- Arlington, VA4 studies
- Detroit, MI4 studies
- St. Louis, MO3 studies
Other studies in San Diego
- Non-Small Cell Lung Cancer48 studies
- Breast Cancer41 studies
- Cancer (all types)32 studies
- Prostate Cancer31 studies
- Metastatic Cancer30 studies
- Colorectal Cancer25 studies
- Ovarian Cancer24 studies
- Pancreatic Cancer24 studies
- Lung Cancer23 studies
- Obesity23 studies
- Heart Failure23 studies
- Depression21 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.